Learn more about how Team Painter is developing an mRNA vaccine to overcome limitations of traditional malaria vaccines.
Despite decades of research, traditional malaria vaccines have limitations, including poor efficacy and interference from previous infection.
We developed an mRNA vaccine incorporating a potent vaccine adjuvant which enables the generation of liver-resident memory T cells to prevent malaria.
Our mRNA vaccine shows promise for effective protection against malaria, particularly in malaria-endemic regions, as it is not impaired by previous exposure to blood-stage infection, unlike traditional vaccines.
Led by Professor Gavin Painter, this team is focused on developing nanomedicines, RNA-based technologies
Read more
A new mRNA vaccine targeting immune cells in the liver could be the key to tackling malaria, a disease that causes over half a million deaths each year according to the World Health Organization, yet has no effective long-lasting vaccine.
Nat Immunol (2023)
